The European Union, with partners from France, Italy, Germany, Israel, Lithuania, Ireland and the Netherlands has launched a €9.2 million Euro-funded research project, called ADIPOA, to find a cure for osteoarthritis. The disease affects more than 70 million EU citizens – 400, 000 of them in Ireland. The most common form of human arthritis, it is characterized by the degeneration of cartilage in joints.
EU Invests In Osteoarthritis Research

The ADIPOA research team is trying to learn how adipose-derived stem cells, injected into diseased joints, can activate the regeneration of cartilage. Fat derived stem cells have become a favored alternative to bone-marrow-derived stem cells because the tissue is easily available through minimally invasive surgical procedures and it is available in large quantities so that doctors can harvest a lot of stem cells at one time. The team has just completed its Phase 1 clinical trial.
Professor Frank Barry, Scientific Director of the Regenerative Medicine Institute at Galway, is a partner in the ADIPOA project. Barry reported, “Until now there were just two possible outcomes for suffers of this progressive and debilitating disease – joint replacement surgery or life-long pain management. From the clinical trials conducted so far, we have seen the first signs of finding a cure .Using the patient’s own stem cells we have been able to treat their diseased joints and relieve their suffering and burden of pain. Whilst we are still in the early stages of clinical trials the results so far are extremely positive such that the use of stem cell therapy for osteoarthritis could become a reality for patients within the next 5 years.”
The projects’ EU funding is under the European Commission’s Seventh Framework Program for Research & Technological Development.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.